Avidity Biosciences First participants in the Phase 1/2 MARINA™ trial dosed with AOC 1001 – Learn More » DELIVERING ON THE RNA REVOLUTION Luke living with DM1 DELIVERING A NEW CLASS OF RNA THERAPEUTICS At Avidity Biosciences, we are driven by our mission: to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapies. We are doing this by realizing the broad and disruptive potential of our Antibody Oligonucleotide Conjugates (AOC™) platform. Beginning with our muscle disease franchise, our programs tackle the root cause of disease. Our innovative pipeline is set to advance and expand into additional cells and tissues, allowing us to address unmet patient needs across a wide-range of therapeutic areas. Platform DELIVERING ON OUR VISION We are delivering a new class of RNA therapeutics - AOCs - which combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Through integrating these proven technologies, our AOC platform is able to deliver to previously inaccessible tissue and cell types and more effectively target the underlying genetic drivers of diseases. With an agile and diverse team, we are advancing and expanding our pipeline programs to offer treatment options for patients and their families. Patients © 2021 Avidity Biosciences EXPLORE About Platform Pipeline Patients Investors Contact Careers CONTACT 10578 Science Center Dr. Suite 125 San Diego, CA 92121 info@aviditybio.com Tel: 858-401-7900 FOLLOW LEGAL Terms of Use Privacy Policy Patents